Deloitte China assists listing of Micot Pharma on SEHK
1st IPO listed under 18A of Hong Kong Stock Exchange by a Xi'an pharmaceutical company
Deloitte China supported the listing of Shaanxi Micot Pharmaceutical Technology Co., Ltd. - B (Micot Pharma, stock code: 02335.HK) on the Stock Exchange of Hong Kong (SEHK) on 24 June 2026. This is the 1st IPO listed under Chapter 18A of the Hong Kong Stock Exchange Main Board Listing Rules (biotech companies) by a Xi’an pharmaceutical company.
In this global offering, Micot Pharma offered 58,054,400 shares at an offer price of HKD18.20 per share, raising approximately HKD1.06 billion.
(From left) Zou Ran, chief financial officer of Micot Pharma; Ashley Wang, Deloitte China’s Audit & Assurance (A&A) manager; Jin Miao, A&A senior manager; Zoey Teng, A&A senior; Catherine Chen, A&A manager; Nicole Liu, A&A senior; Shelley Sun, Xi'an Office managing partner; Dick Kay, National leader of Capital Market Services Group (CMSG); Dr. Wang Bing, chairman of board, chief executive officer and executive director of Micot Pharma; Benjie Chan, Western Region Hong Kong Offering leader of Deloitte China’s CMSG; Shan Li Li, A&A partner and Katherine Liu, A&A manager attend the listing ceremony of Micot Pharma at the Hong Kong Stock Exchange.
(From left) Katherine Liu, Shan Li Li, Shelley Sun, Dr. Wang Bing; Ernest Lee, Deloitte China's Technical partner and a member of the Listing Committee of the SHEK; Benjie Chan, Catherine Chen and Jin Miao attend the listing ceremony of Micot Pharma at the Hong Kong Stock Exchange.
Client overview
Micot Pharma is a R&D-driven innovator. It develops dual- and multi-functional peptide drugs for cardiovascular/cerebrovascular, metabolic, and inflammation/pain diseases.
Micot Pharma is committed to advancing peptide drugs as cornerstone therapies across multiple disease areas. Leveraging over a decade of experience in peptide drug R&D, it has established a fully integrated platform supporting the innovation and industrialization of bi-/multi-functional peptide drug candidates.
As of the latest practicable date, Micot Pharma had developed a globally leading pipeline of bi-/multi-functional peptides and innovative drug candidates, including: (i) its core product, MT1013, a peptide drug that targets both CaSR and OGP receptors, primarily developed for the treatment of CKD-SHPT, with may further be developed for additional indications such as CKD-MBD with Osteoporosis and CKD-SHPT not on dialysis; and (ii) three key products, namely XTL6001, MT1002 and MT200605, as well as other product candidates.
Deloitte's role
The Micot Pharma listing spanned industry cycles, bearing witness to the resilience of the company's and Deloitte's teams. As a core service institution of this new listing engagement, Deloitte China has been deeply involved in the entire process of the IPO. This successful listing demonstrates Deloitte's professional service capabilities in serving clients in capital markets. Our engagement team worked closely with various professional parties, provided high-quality services with rich industry experience and excellent professional capabilities to assist Micot Pharma’s listing on the Main Board of the SEHK.
Deloitte China congratulates Micot Pharma on its successful listing on the SEHK. We will continue to provide high quality professional services and outstanding resources integration to assist more clients to take one-step ahead in today's increasingly competitive and complex business environment.
Deloitte refers to one or more of Deloitte Touche Tohmatsu Limited (“DTTL”), its global network of member firms, and their related entities (collectively, the “Deloitte organization”). DTTL (also referred to as “Deloitte Global”) and each of its member firms and related entities are legally separate and independent entities, which cannot obligate or bind each other in respect of third parties. DTTL and each DTTL member firm and related entity is liable only for its own acts and omissions, and not those of each other. DTTL does not provide services to clients. Please see About Deloitte to learn more.
Deloitte China provides integrated professional services, with our long-term commitment to be a leading contributor to China’s reform, opening-up and economic development. We are a globally connected firm with deep roots locally, owned by our partners in China. With over 20,000 professionals across 31 Chinese cities, we provide our clients with a one-stop shop offering world-leading audit, tax and consulting services.
We serve with integrity, uphold quality and strive to innovate. With our professional excellence, insight across industries, and intelligent technology solutions, we help clients and partners from many sectors seize opportunities, tackle challenges and attain world-class, high-quality development goals.
The Deloitte brand originated in 1845, and its name in Chinese (德勤) denotes integrity, diligence and excellence. Deloitte's global professional network of member firms now spans more than 150 countries and territories. Through our mission to make an impact that matters, we help reinforce public trust in capital markets, enable clients to transform and thrive, empower talents to be future-ready, and lead the way toward a stronger economy, a more equitable society and a sustainable world.
This communication contains general information only, and none of Deloitte Touche Tohmatsu Limited (“DTTL”), its global network of member firms or their related entities (collectively, the “Deloitte organization”) is, by means of this communication, rendering professional advice or services. Before making any decision or taking any action that may affect your finances or your business, you should consult a qualified professional adviser.
No representations, warranties or undertakings (express or implied) are given as to the accuracy or completeness of the information in this communication, and none of DTTL, its member firms, related entities, employees or agents shall be liable or responsible for any loss or damage whatsoever arising directly or indirectly in connection with any person relying on this communication. DTTL and each of its member firms, and their related entities, are legally separate and independent entities.
